Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, this study uncovers a novel NRF2/miR-29b-1-5p/AKT regulatory loop that can regulate the fate (life/death) of MDA-MB-231 cells and suggests this loop as therapeutic target for TNBC.
|
31313842 |
2020 |
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results indicated that dual inhibition of PI3K/Akt and MEK5/ERK5 signaling was more effective at reducing the proliferation and survival of TNBCs than single inhibition of either pathway alone.
|
31464004 |
2020 |
Triple Negative Breast Neoplasms
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been associated with activation of PI3K or AKT and/or deletions of PTEN.
|
31841354 |
2020 |
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> Our results demonstrated that targeting MAT2B could suppress cell growth and migration and induce apoptosis by inhibiting the AKT and ERK pathways in TNBC.
|
31354356 |
2019 |
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings provide a preclinical foundation for targeting both the microtubule cytoskeleton and the PI3K/AKT/mTOR pathway in the treatment of refractory TNBC.
|
31480338 |
2019 |
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data established that APS intervenes with TNBC cell invasion, proliferation, and apoptosis <i>via</i> the PIK3CG/AKT/BCL2 pathway and could thus offer a promising therapeutic strategy for TNBC.
|
31680955 |
2019 |
Triple Negative Breast Neoplasms
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Differential gene expression and AKT targeting in triple negative breast cancer.
|
31320990 |
2019 |
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
We review the evidence for PI3K pathway activation in TNBC, and clinical trial data for PI3K, AKT and mammalian target of rapamycin inhibitors in TNBC.
|
31050709 |
2019 |
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review discusses the potentials and drug discovery perspectives of PI3K/AKT/mTOR as a therapeutic target for effective management of TNBC with anticipated challenges.
|
31520748 |
2019 |
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we investigated whether miR-361-5p can act as a tumor suppressor by targeting required for cell differentiation 1 homolog (RQCD1) and inhibiting epidermal growth factor receptor (EGFR)/phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway in TNBC.
|
29924958 |
2019 |
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alteration of the PI3K/AKT/mTOR pathway is a common genomic abnormality detected in triple-negative breast cancer (TNBC).
|
31703728 |
2019 |
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study examined the effects of tetrandrine suppressing proliferation, targeting LC3, p62, and Beclin-1 autophagy genes by inhibiting PI3K/AKT/mTOR signaling in Triple-negative breast cancer (TNBC) MDA-MB-231 cell.
|
30713576 |
2019 |
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, promising data has been observed in randomized phase II trials of AKT inhibitors in combination with fulvestrant or paclitaxel in metastatic HR-positive, HER2-negative disease and triple negative breast cancer (TNBC), respectively.
|
31828441 |
2019 |
Triple Negative Breast Neoplasms
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we established a FRET biosensor-based high throughput imaging approach to determine ERK and AKT activity in two triple negative breast cancer (TNBC) cell lines HCC1806 and Hs578T.
|
31536726 |
2019 |
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA‑27a promotes tumorigenesis via targeting AKT in triple negative breast cancer.
|
29115608 |
2018 |
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
We studied the role of the AKT pathway and mitochondrial metabolism downstream of Notch signaling in TNBC CSC from cell lines representative of different TNBC molecular subtypes as well as a novel patient-derived model.
|
30564555 |
2018 |
Triple Negative Breast Neoplasms
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we used the Ion Personal Genome Machine (PGM) and Ion Torrent Ampliseq Cancer panel to sequence hotspot regions from PIK3CA, AKT and PTEN genes to identify genetic mutations in 39 samples of TNBC subtype from Moroccan patients and to correlate the results with clinical-pathologic data.
|
30227836 |
2018 |
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> The PI3K/AKT/mTOR pathway is an important oncogenic driver in triple-negative breast cancer (TNBC).
|
29675095 |
2018 |
Triple Negative Breast Neoplasms
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, analysis of 50 triple-negative breast cancer (TNBC) specimens and specific uptake value (SUV) of PET images revealed a positive correlation between miR-155 level and glucose usage in human breast tumors via PIK3R1-PDK/AKT-FOXO3a-cMYC axis.
|
29527004 |
2018 |
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we provide new evidence of the effects of exercise on TNBC prevention, control, and outcomes, based on the inhibition of the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (PKB also known as Akt)/mammalian target of rapamycin (mTOR) (PI3K-Akt-mTOR) signaling.
|
30363988 |
2018 |
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we found that MLN4924 activates the AKT pathway in both HER2-positive and triple-negative breast cancer (TNBC) cell lines.
|
30198810 |
2018 |
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a recently published phase 2 clinical trial, an AKT inhibitor (ipatasertib) improved outcomes in a subset of patients with metastatic TNBC when combined with paclitaxel in the first-line setting.
|
29417298 |
2018 |
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
The tumor suppressing effect of AHNAK in TNBC was associated with the AKT/MAPK signaling pathway and Wnt/β-catenin pathway.
|
28494797 |
2017 |
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
The expression of PKIB in the cytoplasm of tumor is closely related to pAkt and the triple negative breast cancer.
|
28387904 |
2017 |
Triple Negative Breast Neoplasms
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hyper-activation of the MAPK and PI3K-AKT pathways is linked to tumour progression in triple-negative breast cancer (TNBC).
|
28576487 |
2017 |